27 sep: Onsdagens aktier: Pandora tog revanche i lettere positivt marked
28 sep: Bavarian Nordic får ny vaccinebestilling fra USA's regering
27-09-2017 22:18:02

Bavarian Nordic Secures Contract Award for Supply of Freeze-dried IMVAMUNE Smallpox Vaccine to the U.S. Government

Relateret indhold
13 jun - 
Aktier/middag: WDH og GN trækker indekset frem inden re..
12 jun - 
C25-selskaber/Jyske: Dropper dækning af flere selskaber
06 jun - 
Onsdagens aktier: Analysenyt løftede William op i toppe..
Relateret debat
17 jun - 
så ville jeg nok holde pengene i pungen
17 jun - 
Muligt vi ser en mandag med usikkerhed på retningen, me..
17 jun - 
jeg er meget kortsigtet, skal bruge pengene til august,..

  • Initial base award secures additional IMVAMUNE bulk contract of USD 100 million

  • Contract includes initial options valued at USD 439 million

  • Potential for contract value to increase if options to purchase additional IMVAMUNE bulk or freeze dried doses are exercised.

  • Company to host conference call tomorrow at 3:00 pm CEST (09:00 am EDT)

COPENHAGEN, Denmark, September 27, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced the award of a sole source contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS), for the procurement of freeze-dried IMVAMUNE® smallpox vaccine. The potential value of the initial base and optional awards is in excess of USD 539 million.

The initial award in the contract calls for the manufacturing and storage of USD 100 million of IMVAMUNE bulk. This is the third such award to manufacture vaccine bulk; with the two prior orders totaling USD 233 million. The initial options in the contract are divided between two distinct areas, the first of which is the filling and freeze-drying of IMVAMUNE from the three bulk awards, with total potential value of USD 299 million. The second part of the contract contains provisions for clinical development, regulatory commitments, and parts of the establishment and validation of fill/finish activities, with potential value of up to USD 140 million. The award also contains options to acquire additional vaccine bulk and/or freeze-dried doses of IMVAMUNE in the future. 

To ensure the production capacity to secure the future IMVAMUNE stockpile at the U.S. Strategic National Stockpile, Bavarian Nordic will invest approximately USD 75 million over the coming years in the construction of a fill/finish manufacturing line at its facility in Denmark. As part of Bavarian Nordic's long-standing partnership with BARDA, a potential optional award of up to USD 33 million (part of the USD 140 million mentioned above) is dedicated to process transfer, and validation of the new manufacturing line. This strategic investment will allow Bavarian Nordic to recognize the full value chain of the manufacturing process, to maintain control of the product cycle throughout, and the potential to provide these services to third parties in the future. 

"We are proud to be part of a long-standing and successful partnership with BARDA and this latest contract starts a new chapter, as we supply an improved formulation of our vaccine as part of the U.S. government commitment to protect the nation from a smallpox outbreak " said Paul Chaplin, President and Chief Executive Officer of Bavarian Nordic. "Our latest strategic investment that will expand our manufacturing capacities will add value, not only to our partnerships, but also to our proprietary pipeline."

The contents of this announcement do not affect the Company's expectations for the financial results for 2017.

Conference call and webcast

The management of Bavarian Nordic will host a conference call tomorrow, Thursday, September 28, 2017 at 3:00 PM CEST (9:00 AM EDT) to discuss the award of this contract. Dial-in numbers for the conference call are: Denmark: +45 32 71 16 58, UK: +44 (0) 20 3427 1910, USA: +1 212 444 0896. Participant code is 8258368. A live and archived webcast of the call and relevant slides will be available at http://www.bavarian-nordic.com/investor/events.aspx?event=5321.

Federal funding acknowledgements

This project has been funded in whole or in part with federal funds from the HHS Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201700019C.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases, based on the Company's live virus vaccine platform. Through long-standing collaborations, including a collaboration with the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for infectious diseases, including the non-replicating smallpox vaccine, IMVAMUNE®, which is stockpiled for emergency use by the United States and other governments. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Bavarian Nordic and its strategic partner Janssen are developing an Ebola vaccine regimen, and therapeutic vaccines for HPV, HBV and HIV. Additionally, in collaboration with the National Cancer Institute, Bavarian Nordic has developed a portfolio of active cancer immunotherapies, including PROSTVAC®, which is currently in Phase 3 clinical development for the treatment of advanced prostate cancer. The company has partnered with Bristol-Myers Squibb for the potential commercialization of PROSTVAC. For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contacts

Rolf Sass Sørensen

Vice President Investor Relations (EU)

Tel: +45 61 77 47 43

Seth Lewis

Vice President Investor Relations (US)

Tel: +1 978 341 5271

Company Announcement no. 28 / 2017

2017-28-en


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Bavarian Nordic A/S via Globenewswire

Vedhæftet fil: 818092.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
13 jun
BAVA
7
12 jun
BAVA
Troede du fik dem i aftenhandlen til 250😁😁
5
12 jun
BAVA
Det bakker 100% op omkring min holding som er køb af aktien..   https://getvisualtv.net/stream/?daf-..
4
11 jun
BAVA
Helt ærligt Enkommentar, stop dine belærende indlæg. Du laver selv jævnligt indlæg, der afslører at ..
3
12 jun
BAVA
Jeg mener de sagde følgende: De tager 200 raske menesker isolere dem - giver 50% RSV vaksine og rest..
2
16 jun
BAVA
RSV data kommer snart ... vi er på vej mod 240-250 efter min mening
1
15 jun
BAVA
eller går vi i 215 som tigerdyret skriver
1
14 jun
BAVA
Jeg er jo typisk ikke en tiger, der træder folk over tæerne, men jeg må da indrømme, at baronen for ..
1
14 jun
BAVA
Jeg har fuldt Bavarian Nordic mindste lige så meget som dig,  jeg kender deres pipeline og produkter..
1
14 jun
BAVA
tja men hvorfor skal de bruge alt for lang tid på at rapportere deres resultater, der er faktisk en ..
1

Spar Nord optager lån på 400 mio. kr.

15-06-2018 13:48:15
Spar Nord vil i næste uge optage et lån på 400 mio. kr., der har status af supplerende kapital. Et mindre antal professionelle investorer har lånt banken pengene. Lånet har en løbetid på ti år, men der er mulighed for at betale det ud efter fem år. De første fem år er renten på 2,53 pct., og udstedelsen vil gælde fra 19. juni, oplyser Spar Nord i en meddelelse til fondsbørsen. Supplerende kapital ..

Mærsk: Fragtraterne falder for anden uge i træk

15-06-2018 09:23:33
Spotpriserne på containerfragt faldt 3,5 pct. til 777,70 i denne uge ifølge rateindekset Shanghai Containerized Freight Index (SCFI). Dermed fortsætter sidste uges fald, efter at priserne ellers var steget de to foregående uger.Indekset har bevæget sig en del, siden det var nede at vende i årets bund i 568,68 i slutningen af marts.SCFI-indekset sammensættes på baggrund af spotprisen på fragt fra S..

Pandora/Carnegie: Nedslående meldinger om salget i Storbritannien

15-06-2018 07:18:38
Der er tegn på, at det danske smykkeselskab Pandora klarer sig dårligt i Storbritannien.Sådan lyder det i en analyse udarbejdet af investeringsbanken Carnegie ifølge Bloomberg News.Carnegie har ifølge mediet fået "nedslående" meldinger fra flere af Pandoras franchisetagere i Storbritannien, og det fremgår desuden af analysen, at salget indtil videre i år er faldet med op mod 15 pct.Investeringsban..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Bavarian Nordic A/S 205,50 -1,5% Fald i aktiekurs
Bavarian Nordic Ord Shs 205,50 -1,5% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer  |  Cookie- og privatlivspolitik  |  Persondatapolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
18. juni 2018 05:58:06
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180613.1 - EUROWEB3 - 2018-06-18 05:58:06 - 2018-06-18 05:58:06 - 1 - Website: OKAY